Global Markets Directs, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Review, H2 2014, provides an overview of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)s therapeutic pipeline.
To Read the Complete Report with Toc Visit: http://www.marketresearchreports.biz/analysis/238889
This report provides comprehensive information on the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/238889
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Introduction
Global Markets Direct Report Coverage
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Overview
Therapeutics Development
Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Overview
Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Comparative Analysis
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics under Development by Companies
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics under Investigation by Universities/Institutes
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Products under Development by Companies
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Products under Investigation by Universities/Institutes
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Companies Involved in Therapeutics Development
Genzyme Corporation
La Jolla Pharmaceutical Company
Merck & Co., Inc.
Okklo Life Sciences BV
Orphazyme ApS
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
arimoclomol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclodextrins + delta-tocopherol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GZ-402665 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LJPC-0712 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ML-SA1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OKL-1014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OR-0005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target Cholesterol for Niemann-Pick Disease Type C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cancer, Pain, Retinal Degeneration and Niemann-Pick Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Recent Pipeline Updates
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Dormant Projects
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Product Development Milestones
Featured News & Press Releases
Jul 17, 2013: La Jolla Pharmaceutical Company Receives Orphan Designation From FDA
Apr 03, 2013: Old Drug Offers New Treatment For Niemann-Pick Type C, Study Finds
Feb 21, 2013: Orphazyme Receives Orphan Drug Designation For OR0005 In EU
Jan 23, 2013: NIH Clinical Trial Begins For Treatment Of Niemann-Pick Disease Type C1
Mar 13, 2012: U-M biologists Find Potential Drug That Speeds Cellular Recycling
Sep 19, 2001: Recombinant Human Acid Sphingomyelinase For The Treatment Of Niemann-Pick Disease, Type B Receives Orphan Drug Designation From Committee For Orphan Medicinal Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), H2 2014
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Genzyme Corporation, H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by La Jolla Pharmaceutical Company, H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Merck & Co., Inc., H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Okklo Life Sciences BV, H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Orphazyme ApS, H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Therapeutics - Recent Pipeline Updates, H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Dormant Projects, H2 2014
List of Figures
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), H2 2014
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Visit: http://www.prnewswire.com/news/marketresearchreports.biz
To Read the Complete Report with Toc Visit: http://www.marketresearchreports.biz/analysis/238889
This report provides comprehensive information on the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/238889
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Introduction
Global Markets Direct Report Coverage
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Overview
Therapeutics Development
Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Overview
Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Comparative Analysis
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics under Development by Companies
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics under Investigation by Universities/Institutes
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Products under Development by Companies
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Products under Investigation by Universities/Institutes
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Companies Involved in Therapeutics Development
Genzyme Corporation
La Jolla Pharmaceutical Company
Merck & Co., Inc.
Okklo Life Sciences BV
Orphazyme ApS
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
arimoclomol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclodextrins + delta-tocopherol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GZ-402665 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LJPC-0712 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ML-SA1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OKL-1014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OR-0005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target Cholesterol for Niemann-Pick Disease Type C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cancer, Pain, Retinal Degeneration and Niemann-Pick Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Recent Pipeline Updates
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Dormant Projects
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Product Development Milestones
Featured News & Press Releases
Jul 17, 2013: La Jolla Pharmaceutical Company Receives Orphan Designation From FDA
Apr 03, 2013: Old Drug Offers New Treatment For Niemann-Pick Type C, Study Finds
Feb 21, 2013: Orphazyme Receives Orphan Drug Designation For OR0005 In EU
Jan 23, 2013: NIH Clinical Trial Begins For Treatment Of Niemann-Pick Disease Type C1
Mar 13, 2012: U-M biologists Find Potential Drug That Speeds Cellular Recycling
Sep 19, 2001: Recombinant Human Acid Sphingomyelinase For The Treatment Of Niemann-Pick Disease, Type B Receives Orphan Drug Designation From Committee For Orphan Medicinal Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), H2 2014
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Genzyme Corporation, H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by La Jolla Pharmaceutical Company, H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Merck & Co., Inc., H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Okklo Life Sciences BV, H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Orphazyme ApS, H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Therapeutics - Recent Pipeline Updates, H2 2014
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Dormant Projects, H2 2014
List of Figures
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), H2 2014
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Visit: http://www.prnewswire.com/news/marketresearchreports.biz
No comments:
Post a Comment